Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Outlook Therapeutics (OTLK) over the last 7 years, with Q4 2025 value amounting to $12.2 million.

  • Outlook Therapeutics' Operating Expenses changed N/A to $12.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.5 million, marking a year-over-year decrease of 5698.23%. This contributed to the annual value of -$3.1 million for FY2025, which is 18427.33% down from last year.
  • Per Outlook Therapeutics' latest filing, its Operating Expenses stood at $12.2 million for Q4 2025.
  • Outlook Therapeutics' 5-year Operating Expenses high stood at $16.8 million for Q2 2025, and its period low was -$29.9 million during Q3 2025.